Quintet Private Bank Europe S.A. Acquires 28,629 Shares of Thermo Fisher Scientific Inc. $TMO

Quintet Private Bank Europe S.A. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 48.2% during the third quarter, Holdings Channel reports. The institutional investor owned 88,084 shares of the medical research company’s stock after purchasing an additional 28,629 shares during the quarter. Thermo Fisher Scientific comprises 2.8% of Quintet Private Bank Europe S.A.’s investment portfolio, making the stock its 9th biggest holding. Quintet Private Bank Europe S.A.’s holdings in Thermo Fisher Scientific were worth $59,461,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $15,501,867,000. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $382,547,000. Bank of New York Mellon Corp acquired a new position in Thermo Fisher Scientific during the second quarter worth about $1,974,561,000. Bank of America Corp DE purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $1,952,930,000. Finally, Auto Owners Insurance Co lifted its position in shares of Thermo Fisher Scientific by 57,845.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after acquiring an additional 2,423,706 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on TMO. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research report on Monday, July 6th. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research report on Wednesday. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 28th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $635.55.

Thermo Fisher Scientific Trading Down 2.6%

Shares of TMO traded down $17.20 during mid-day trading on Thursday, reaching $644.86. The company had a trading volume of 1,385,840 shares, compared to its average volume of 2,247,130. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $694.33. The stock has a market cap of $238.44 billion, a price-to-earnings ratio of 34.65, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a fifty day simple moving average of $624.23 and a 200-day simple moving average of $539.29.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock worth $44,122,820 over the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.